The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of Intensity Therapeutics Inc (NASDAQ: INTS) was $0.27 for the day%, Up $0.04% from the previous closing price of $0.27. In other words, the price has increased by $0.04 from its previous closing price. On the day, 3.31 million shares were traded. INTS stock price reached its highest trading level at $0.28 during the session, while it also had its lowest trading level at $0.2547.
Ratios:
Our analysis of INTS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.40 and its Current Ratio is at 1.40. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, INTS now has a Market Capitalization of 12705580 and an Enterprise Value of 10614586.
Stock Price History:
The Beta on a monthly basis for INTS is 3.77, which has changed by -0.93594307 over the last 52 weeks, in comparison to a change of 0.17279088 over the same period for the S&P500. Over the past 52 weeks, INTS has reached a high of $4.70, while it has fallen to a 52-week low of $0.19. The 50-Day Moving Average of the stock is -20.41%, while the 200-Day Moving Average is calculated to be -83.45%.
Shares Statistics:
INTS traded an average of 3.62M shares per day over the past three months and 6465180 shares per day over the past ten days. A total of 26.17M shares are outstanding, with a floating share count of 14.05M. Insiders hold about 46.12% of the company’s shares, while institutions hold 10.32% stake in the company. Shares short for INTS as of 1752537600 were 387444 with a Short Ratio of 0.11, compared to 1749772800 on 659567. Therefore, it implies a Short% of Shares Outstanding of 387444 and a Short% of Float of 1.87.
Earnings Estimates
The market rating for Intensity Therapeutics Inc (INTS) is a result of the insights provided by 1 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.15, with high estimates of -$0.15 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.41 and -$0.7 for the fiscal current year, implying an average EPS of -$0.56. EPS for the following year is -$0.47, with 2.0 analysts recommending between -$0.45 and -$0.5.
